The content on this site is intended for healthcare professionals only
Dr Richard Kim speaks to ecancer at the ASCO Direct Highlights 2022 Miami Symposium about some of the new research into colorectal malignancies that was presented at this year's ASCO.
He first describes a trial that used immunotherapy in early locally advanced colorectal cancer demonstrating a clinical response of 100%.
Dr Kim also details studies investigating the use of EGFR inhibitors and a trial that looked into the predictive nature of tumour DNA.
ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer
Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy
Revolutionising myeloma treatment through immune profiling
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
